Clin Infect Dis 2006; 43: 365–372. 10  Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004; 38: e79–e80. 11  Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006; 13: 683–689. 12  Kovari H, Ledergerber B, Peter U et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49: 626–635. 13  Solas

C, Pambrun E, Winnock M et al. for the ANRS CO-13 HEPAVIH Study Group. Ribavirin Vorinostat chemical structure and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS 2012; 26: 2193–2199. 14  Vispo E,

Barreiro P, Pineda JA et al. Low response to pegylated click here interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13: 429–437. 15  Laufer N, Laguno M, Perez I et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008; 13: 953–957. 16  Mira JA, Lopez-Cortes LF, Barreiro P et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008; Ceramide glucosyltransferase 62: 1365–1373. 17  Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004; 39: 129–132.

18  Zylberberg H, Pialoux G, Carnot F et al. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998; 27: 1255–1258. 19  Moreno A, Quereda C, Montes M et al. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir. J Acquir Immune Defic Syndr 2012; 61: e47–e49. 20  Hulskotte E, Feng HP, Xuan F et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. 19th Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA. March 2012 [Abstract 771LB]. 21 Boceprevir SPC July 2012 22 Telaprevir SPC Nov 2012 23  van Heeswijk R, Garg V, Boogaerts G et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago IL. September 2011 [Abstract A1-1738a].